跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SPEVIGO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SPEVIGO
Authorized
STANDARD
SPEVIGO
boehringer ingelheim (canada) ltd ltee
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
1bf47f84b3b0dd43
Company
boehringer ingelheim (canada) ltd ltee
Type
Standard
Approval Details
Approval Id
1bf47f84b3b0dd43
Drug Approval Canada Name
SPEVIGO
Product Name
SPEVIGO
Status
Marketed
Status Date
2023-05-11
Original Market Date
2023-05-11
Din
02536455
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Prescription , Schedule D
Ahfs
84:06.28
Atc Original
L04AC22 SPESOLIMAB
Atc Name
l 04 ac 22
Aig Number
0164521001
Company Name
boehringer ingelheim (canada) ltd ltee
Company Address
5180 South Service Road, Burlington, Ontario, Canada, L7L 5H4
Active Ingredients
SPESOLIMAB
60 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
1bf47f84b3b0dd43
Type
Standard
Back to Health Canada Approvals